Clinical Trial Update: Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors [Phase 1]

View source ↗

Summary

GAIA-102 is being evaluated in a Phase 1 trial for refractory/relapsed neuroblastoma and other pediatric solid tumors, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• GAIA-102

Snippet

Sponsor: Kyushu University | Conditions: Refractory/Relapse Neuroblastoma, Pediatric Solid Tumors | Phase 1 | Status: RECRUITING